Publicaciones en colaboración con investigadores/as de University of Glasgow (14)

2022

  1. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome

    Annals of the rheumatic diseases, Vol. 81, Núm. 6, pp. 768-779

  2. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry

    Annals of the rheumatic diseases, Vol. 81, Núm. 5, pp. 695-709

2020

  1. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2

    Annals of the Rheumatic Diseases, Vol. 79, Núm. 7, pp. 851-858

2017

  1. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

    Annals of the Rheumatic Diseases, Vol. 76, Núm. 6, pp. 960-977

2015

  1. Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis

    Clinical and Experimental Rheumatology, Vol. 33, pp. 31-35

2014

  1. A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility

    Arthritis Research and Therapy, Vol. 16, Núm. 1

2013

  1. Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab

    Annals of the Rheumatic Diseases, Vol. 72, Núm. 1, pp. 83-88

2012

  1. Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial

    Arthritis and Rheumatism, Vol. 64, Núm. 8, pp. 2504-2517

  2. Influence of the IL6 gene in susceptibility to systemic sclerosis

    Journal of Rheumatology, Vol. 39, Núm. 12, pp. 2294-2302

  3. Treating rheumatoid arthritis to target: Recommendations of an international task force

    Revmatologiia (Bulgaria), Vol. 20, Núm. 2, pp. 5-16

2010

  1. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

    Annals of the Rheumatic Diseases, Vol. 69, Núm. 6, pp. 964-975

  2. The Eular recommendations for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs

    Rheumatologia, Vol. 24, Núm. 4, pp. 143-158

  3. Treating rheumatoid arthritis to target: Recommendations of an international task force

    Annals of the Rheumatic Diseases, Vol. 69, Núm. 4, pp. 631-637

2009

  1. Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety Results of a randomized, placebo-controlled study

    Arthritis and Rheumatism, Vol. 60, Núm. 4, pp. 976-986